AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme
Phase 1b of the study, will evaluate the safety and tolerability of AQ4N treatment at three different dose levels.

Phase 2a of the study, will further evaluate the safety, tolerability, and in addition efficacy of AQ4N treatment at a tolerated dose selected from Phase 1b.
Glioblastoma Multiforme
DRUG: AQ4N|DRUG: Temozolomide|PROCEDURE: Radiotherapy
Phase 1b: Evaluation of the safety and tolerability of AQ4N in combination with radiation therapy and temozolomide (TEMODARÂ®)for the treatment of glioblastoma multiforme (GBM). Dose levels for the Phase 2a will be selected.|Phase 2a: Rate of progression-free survival at 6 months.
Phase 2a: Rate of progression-free survival at 12 months|Percent of subjects alive at 12 months|Duration of progression-free survival|Time to progression|Duration of overall survival
Phase 1b of the study, will evaluate the safety and tolerability of AQ4N treatment at three different dose levels.

Phase 2a of the study, will further evaluate the safety, tolerability, and in addition efficacy of AQ4N treatment at a tolerated dose selected from Phase 1b.